For the first time, we found that use of the NRF2 antagonist ML385 (ML385 is an innovative and selective NRF2 inhibitor that can specifically bind the Neh1 domain of NRF2, inhibiting downstream target gene expression) could induce the apoptosis of AML cells. This evidence concerns the gene NEIL1 and acute myeloid leukemia.